Pharma industry reports 66 deals worth $26.1 billion in December 2021: GlobalData

The industry reported 117 venture capital (VC) deals worth $3.8 billion in December 2021, compared to the last 12-month average of 179 deals worth $5.4 billion

The pharma industry reported 66 deals worth $26.1 billion as compared to the last 12-month average (December 2020 to November 2021) of 98 deals worth $21.6 billion, GlobalData has said.

In a statement, the company said that CSL to acquire Vifor Pharma for approximately $12.3 billion; Pfizer Inc to acquire Arena Pharmaceuticals Inc for a total equity value of approximately $6.7 billion; and Triton Investment Management through Triley Bidco, to acquire entire issued and to be issued ordinary share capital of Clinigen Group Plc, for a consideration of approximately $1.6 billion were the three major deals that contributed 78.5 per cent of the total deal value during December 2021.

The industry reported 117 venture capital (VC) deals worth $3.8 billion in December 2021, compared to the last 12-month average (December 2020 to November 2021) of 179 deals worth $5.4 billion, the statement added.

It also notified that Odyssey Therapeutics Inc, raising $218 million in series A financing to advance next-generation inflammation and Oncology medicines; Beijing Anshi Biotechnology Company raising $200 million in series A financing; and Avistone Pharmaceuticals raising $200 million in series A financing to support the accelerated development of its existing drug candidate and expand its product pipeline were the major VC deals reported in December 2021.

GlobalDatapharma dealspharma industry
Comments (0)
Add Comment